PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $2.34B
This Quarter Return
+39.58%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$2.13B
AUM Growth
+$668M
Cap. Flow
+$302M
Cap. Flow %
14.15%
Top 10 Hldgs %
66.13%
Holding
36
New
6
Increased
15
Reduced
8
Closed
6

Top Buys

1
NUVL icon
Nuvalent
NUVL
$163M
2
IRON icon
Disc Medicine
IRON
$64.3M
3
ARGX icon
argenx
ARGX
$61.3M
4
ASND icon
Ascendis Pharma
ASND
$44.3M
5
ACLX icon
Arcellx
ACLX
$39.2M

Top Sells

1
UTHR icon
United Therapeutics
UTHR
$69.4M
2
INCY icon
Incyte
INCY
$52.7M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
$34.7M
4
TGTX icon
TG Therapeutics
TGTX
$24.7M
5
VRNA
Verona Pharma
VRNA
$15.1M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
VOR icon
26
Vor Biopharma
VOR
$253M
$14.5M 0.68%
6,457,293
-4,174
-0.1% -$9.39K
CRGX
27
DELISTED
CARGO Therapeutics
CRGX
$7.72M 0.36%
+333,333
New +$7.72M
ZNTL icon
28
Zentalis Pharmaceuticals
ZNTL
$123M
$6.06M 0.28%
+400,000
New +$6.06M
JBIO
29
Jade Biosciences, Inc. Common Stock
JBIO
$247M
$3.24M 0.15%
+4,092
New +$3.24M
COGT icon
30
Cogent Biosciences
COGT
$1.83B
– –
-225,605
Closed -$2.2M
ETNB icon
31
89bio
ETNB
$1.36B
– –
0
– –
INCY icon
32
Incyte
INCY
$17B
– –
-912,497
Closed -$52.7M
ROIV icon
33
Roivant Sciences
ROIV
$8.67B
– –
-1,081,767
Closed -$12.6M
SNDX icon
34
Syndax Pharmaceuticals
SNDX
$1.4B
– –
-2,390,077
Closed -$34.7M
UTHR icon
35
United Therapeutics
UTHR
$17.7B
– –
-307,314
Closed -$69.4M
VRNA
36
Verona Pharma
VRNA
$9.18B
– –
-926,432
Closed -$15.1M
1
2